Background Anaemia is a major cause of morbidity and mortality in low-income countries. Primary health-care workers in resource-poor settings usually diagnose anaemia clinically, but this is inaccurate. The WHO Haemoglobin Colour Scale (HCS) is a simple, cheap quantitative method to assess haemoglobin concentration outside of the laboratory. We systematically reviewed the literature to assess the accuracy of the HCS in primary care to diagnose anaemia, and compared this with clinical assessment.
Introduction
Anaemia is a major global cause of maternal, perinatal, and child mortality. Additionally, it causes low birthweight, impaired or delayed child physical and mental development, and an increased susceptibility to infections, 1 and contributes greatly to economic loss due to reduced productivity of workers. 2 About 1·62 billion people are aff ected. 1 Most are non-pregnant women (468·4 million), preschool age children (293·1 million), and pregnant women (56·4 million) predominantly in low-income countries, where prevalence rates are up to fi ve times higher than in high-income countries and are inversely correlated with economic status. 3, 4 In these low-income societies, iron defi ciency anaemia is believed to account for about 50% of all cases of anaemia, 5 but other causes are frequent and often co-exist, including malnutrition, micronutrient defi ciencies, parasitic infections, other chronic infl ammatory conditions, or hereditary haemoglobinopathies. 3 Accurate quantitative point-of-care diagnostic tests are able to confi rm the diagnosis of anaemia through measurement of a decreased amount of red blood cells or decreased haemoglobin concentration in the blood, 6 but these are not suitable in most primary health-care settings with very low resources, because they either require constant quality control by trained staff , use toxic or expensive reagents and consumables, or depend on an electricity supply. 7 Diagnosis is thus often based on clinical signs alone such as conjunctival, palmar, and nailbed pallor. None of these signs, whether combined or singly, yield an acceptable diagnostic accuracy. 8 This leaves many cases undetected and untreated and also poses the risk of unnecessary and potentially harmful blood transfusions, increasing the risk of transmission of blood-borne pathogens, and wasting resources in case of misdiagnosed severe anaemia.
In response to the need for a "simple, cheap, and robust device to measure haemoglobin by health workers outside the laboratory" 9,10 the WHO Haemoglobin Colour Scale (HCS) was developed and has been produced and distributed under licence agreement by Copack (Oststeinbek, Germany) since 2001. [10] [11] [12] The scale comprises a small card of six shades of red (lighter to darker), each representing a haemoglobin concentration of 40 g/L, 60 g/L, 80 g/L, 100 g/L, 120 g/L, and 140 g/L, respectively. A drop of blood absorbed onto a standardised chromatography fi lter paper is compared with the colour scale, allowing assessment of the patient's haemoglobin concentration, including an estimation of intermediate results, in 10 g/L steps. 13 The usefulness of the device in practice has been disputed, 14, 15 but in 2005 a systematic review of 14 studies showed that, under ideal conditions, the HCS might improve diagnosis of mild and moderate anaemia with reasonable accuracy (sensitivities from 85% to 99% and specifi cities from 91% to 100% in fi ve laboratory-based studies). 16 Ideal conditions are defi ned as studies taking place in a laboratory setting, including trained laboratory staff operating or supervising the HCS measurements after intensive training, from blood samples of hospital populations or blood donors. The diagnostic accuracy tended to be lower in the four so-called real-life studies (sensitivities 76-88%, apart from one outlier, and specifi cities from 41% to 100%), leading to the conclusion that further research was needed to assess the usefulness of the HCS in real-life situations. Real life conditions are defi ned as studies that were carried out in patient populations attending routine primary health clinics or public schools, with the HCS undertaken by primary health-care workers or a person with comparable skills or training. Only a minority (5 of 14) compared the accuracy of HCS with clinical diagnosis. We are aware of no systematic reviews of the performance of HCS since 2005, although additional "real life" studies have been published.
We aimed to do an updated systematic review to assess the accuracy of the HCS to diagnose anaemia and severe anaemia in resource-poor primary health-care settings compared with the accuracy of diagnosis by clinical assessment, wherever such data are available.
Methods

Search strategy and selection criteria
Following PRISMA guidelines, we searched the electronic databases MEDLINE, EMBASE, SCOPUS, Web of Science, Cochrane library, CINAHL plus, Popline, Reproductive Health Library, TRIP Database, ADOLEC, BDENF, DESASTRES, HISA, MedCarib, LILACS, IMEMR, IMSEAR, WPRIM, and Google Scholar, all from inception up to Nov 14, 2014 . To increase sensitivity of the search strategy, 17 we searched only the keywords "haemoglobin colour scale" without any fi lters using alternative spellings in English, Spanish, and French. A citation search on "Critchley and Bates 2005 systematic
Research in context
Evidence before the study The WHO Haemoglobin Colour Scale (HCS) became commercially available in 2001 as an instrument for health-care workers in resource-poor settings, who usually have to base the diagnosis of anaemia on signs and symptoms, to quantitavely assess the anaemia status of their patients. The fi rst and only systematic review to date to assess the diagnostic accuracy of the HCS was published in 2005, which included 14 studies, but most of these were laboratory-based with only four taking place in primary care in low-income settings, under which the HCS is supposed to be used in practice. The reported estimates of diagnostic accuracy from this 2005 review were very heterogeneous (sensitivity 75-97% and specifi city 41-98% for the detection of anaemia), and were less accurate in the four fi eld studies (sensitivity 76-88%; specifi city 41-100%). The authors did not compute summary estimates from individual studies, except for the fi ve laboratory studies.
Added value of this study
We restricted our systematic review to real life studies (n=14), identifying ten more than available at the time of the previous review. We were also able to compare the performance of the HCS directly against the diagnosis of anaemia by clinical signs, because most studies directly compared these two tests. This is important because clinical assessment is the standard procedure to diagnose anaemia in most primary health-care settings in low-income countries. We also estimated diagnostic accuracy for simultaneous testing (HCS and clinical signs). Despite heterogeneous outcomes, we undertook meta-analysis of individual studies using the bivariate random eff ects model, and we used an evidence informed tool (QUADAS 2) for the assessment of the methodological quality of studies, allowing a series of sensitivity analyses.
Implications of all the available evidence
There is sound evidence that the HCS can improve the accuracy of diagnosis of anaemia and severe anaemia by primary health-care workers under resource-poor conditions. This fi nding is consistent in a variety of sensitivity analyses accounting for study quality and threshold eff ects. The HCS is signifi cantly more sensitive for the diagnosis of anaemia than assessment of clinical signs, and the improvement in sensitivity could be clinically important in practice. Evidence concerning how training and supervision might aff ect the overall performance of the device, as well as its cost-eff ectiveness in reducing anaemia-related mortality and morbidity in practice, is lacking. review 16 " was done in Medline+Embase (Ovid), Scopus, Web of Science, Cinahl plus, and Google scholar. Both authors independently screened the titles and abstracts of all records retrieved and checked the reference lists of eligible articles for further studies; any disagreements were resolved by discussion (appendix p 1).
We included all studies comparing the diagnostic accuracy of the HCS with any reference method (gold standard) to diagnose anaemia under real life conditions as defi ned before. There were no restrictions based on sample size, location, background morbidities, or anaemia prevalence. Studies done in hospitals, laboratories, or blood banks were excluded because they are not generalisable towards primary health-care in lowresource settings.
Data extraction and quality assessment
Both authors independently extracted data including the main study outcomes, study characteristics, and qualityrelated information based on WHO recommendations for HCS evaluations (appendix p 2). 12 We assigned tailored quality-relevant criteria to the domains "patient selection", "index test", "reference standard test", and "fl ow and timing", as proposed in the QUADAS-2 instrument 18 and applied customised signalling questions (table 1) to each individual study to judge whether the risk of bias and applicability concerns to our review objectives were either "high" or "low". The rating "unclear" was only used when the publication did not report quality-relevant data, when the inter-rater reliability was not assessed, or if only one operator did all HCS readings. Again, both authors independently extracted data for all these aspects of quality using a standardised form. Any disagreements were resolved by discussion between authors.
Statistical analyses
Both authors independently extracted the study outcomes for true positive, true negative, false positive, and false negative test results into 2 × 2 tables. The haemoglobin cut-off level in children aged 6-59 months and during pregnancy for diagnosing anaemia was 110 g/L and for diagnosing severe anaemia was 70 g/L according to WHO recommendation. 19 Studies with a diff erent threshold for anaemia and severe anaemia were included in the metaanalysis, but excluded in a sensitivity analysis. We assessed heterogeneity between studies through creation of forest plots and summary ROC curves.
Overall summary estimates
We used the bivariate random eff ects model to combine data across all included studies. This model analyses pairs of sensitivity and specifi city estimates jointly, accounting for possible correlation between both measures within (using a random eff ects model) and between studies (assuming normal distribution), hence preserving the twodimensional nature of the original data. 20 We pooled data for the HCS and clinical assessment separately. In a series of sensitivity analyses, we excluded diff erent subsets of studies to explore whether the exclusion of studies with high risk of bias, studies that did not adjust for several readings of HCS results from the same patient, and studies using diff erent cut-off s for anaemia and severe anaemia would aff ect the pooled accuracy estimates. We then also repeated analyses restricted to the studies that compared the HCS directly with clinical diagnosis, to assess whether confounding by study was aff ecting comparisons.
Comparison of the diagnostic accuracy
We compared the diagnostic accuracy of the HCS with clinical diagnosis in a meta-regression analysis (adding test as a covariate), allowing for covariance both between and within these two "tests". Again, we used a bivariate random eff ects model. We accounted for the correlation expected when two diff erent tests take place in the same study population, and also tested whether the variances of the random eff ects diff ered between tests. For severe anaemia, this full model did not converge due to the smaller number of studies. We thus entered the type of "test" as a covariate with random eff ects; an approach that has been shown to produce similar results, 21 but with the limitation that we can only test for overall diff erences in diagnostic accuracy rather than specifying whether it is the expected sensitivities or specifi cities that diff er. We undertook these models in all studies initially and then only in those studies that examined the performance of both methods. This also allowed us to estimate a pooled accuracy for simultaneous testing, which we assumed to be routine practice.
Meta-regression analysis
Using the same bivariate random eff ects model, we undertook meta-regression analysis with the addition of covariates in sequence to assess whether the following variables could explain any of the heterogeneity between studies: (1) level of training (greater or less than half a See Online for appendix (4) the population type (women or children); (5) anaemia prevalence (40% or higher compared with less than 40%). In this meta-regression, we assumed that training levels were "low" for the four studies that did not report this and that the type of blood sample was diff erent for the three studies that did not state this clearly. Data were analysed with Review manager version 5.3 and STATA 12 statistical software packages metandi, gllamm, and xtmelogit for meta-analysis and metaregression modelling (appendix p 3). 20, 22 
Risk of bias
Role of the funding source
There was no external funding for this study. The funding institution of JC had no role in the design and development, data extraction, analysis and interpretation of the data, or preparation, review, or approval of the paper. HM had full access to all data. HM and JC both had the decision to submit for publication.
Results
Of 141 records screened for eligibility based on titles and abstracts, 98 papers were excluded based on titles and abstracts, and 43 full-text articles were assessed for eligibility (fi gure 1; appendix p 4). 29 articles were excluded because they did not meet the previously defi ned real-life inclusion criteria: 14 were undertaken in blood banks, eight in hospitals, one in a laboratory, three had a mixed fi eld or laboratory design, and two did not report diagnostic accuracy data. For one congress abstract 23 information about whether it was fi eld or laboratory [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Five of the 14 included studies were done in low-income countries and nine in lower middle-income countries: seven in sub-Saharan Africa, one in upper Egypt, three in India, two in Sri Lanka, and one in Indonesia. All but two 25, 28 were located in rural areas (table 2) . Two studies were embedded into larger morbidity surveys, 32, 35 and one study retrospectively investigated the use of HCS as part of a general survey of quality of primary health-care services in Sri Lanka. 27 Two studies examined patients attending hospitals and primary health-care facilities in rural communities. 29, 31 In both cases only the data from the fi eld studies were included in this review. One study examined both children and pregnant women. 29 For practical reasons we regarded these data as two separate studies: one in children (Lindblade 2006c ) and the other one in pregnant women (Lindblade 2006p) .
Seven studies 24, 26, 29, 30, 33, 35, 37 included children (aged from neonates to 11 years), seven studies enrolled pregnant women 25, [27] [28] [29] 31, 32, 36 and one included women of reproductive age irrespective of their pregnancy status. 34 The absolute range of anaemia prevalence was 2-83% (median 58%). Only 11 of 15 studies assessed severe anaemia; in two of these studies no cases were found either by HCS or the reference test. 26, 27 In the remaining nine studies with available data, 20% was the highest prevalence reported in one outlier; 31 in the remaining studies prevalence of severe anaemia varied between 0·6% and 10% (median 2%).
Sample sizes ranged between 101 and 1529. In two studies 24, 36 the samples were read more than once by diff erent assessors. We report main results excluding these two studies because they inappropriately analysed all ratings of the scale, rather than patients assessed (appendix p 3).
Training intensity varied widely from 1 h 24 to 2 days, 28,31 including one case in which the main study was only started after two raters had reached excellent agreement in a preliminary training pilot. 33 Six studies did not report any information about training. [25] [26] [27] 32, 35, 37 Nine studies used capillary blood samples for the HCS test, 24, 26, 28, 29, 31, [34] [35] [36] three studies did not report which kind of samples were used, 25, 27, 30 one used venous blood for both the HCS and the reference test, 33 and one used umbilical cord blood at birth and capillary blood in the follow-up for both tests. 37 Ten studies used the same kind of sample for both tests, 24, 26, 28, 29, 31, [33] [34] [35] 37 in four studies venous blood samples for the reference test were tested in distant laboratories, 27, 32, 33, 36 two of these against capillary blood samples for the HCS. 32, 36 In three studies, the origin of the blood sample was not disclosed for either one or both tests. 25 HemoCue (HemoCue AB, Ängelholm, Sweden) from capillary blood samples was the most frequent reference standard test (n=9) for practical reasons. Two studies used inappropriate point-of-care methods as reference tests: Sahli's haemometer 25 and the fi lter paper cyanmethaemoglobin method. 35 In ten studies, the investigators directly compared the performance of clinical assessment for anaemia with the HCS (table 2) . 24, 25, [27] [28] [29] [30] [31] 35, 36 We detected high risk of bias in fi ve studies 25, 27, 32, 35, 37 and had severe applicability concerns about nine of the 14 studies. In all but two studies 24, 28 incomplete reporting demanded an unclear rating in one or more quality relevant domains (fi gure 2; 24 and van den Broek (1999) 36 allowed multiple observers to assess the same HCS specimen from some of the participants, see main text for details. We report this result as the main pooled analysis since it only includes statistically unbiased studies. The diff erence between the sensitivity of the HCS and clinical assessment to diagnose anaemia is statistically signifi cant (p=0·008). The diff erence between the specifi city of the HCS and clinical assessment to diagnose anaemia was not statistically signifi cant (p=0·825). For severe anaemia the overall diagnostic accuracy of the HCS is signifi cantly higher than for clinical assessment (p<0·0001). †van Rheenen (2007), 37 Sinha (2008) , 35 Bala (2012), 25 Prataphan (2011), 32 and Chathurani (2012) 27 34 tested pregnant and non-pregnant women at the same threshold (<120 g/L).
Table 4: Sensitivity analysis of pooled estimates for HCS and clinical assessment accuracy
The diagnostic accuracy of the HCS to diagnose anaemia varied widely across individual studies; sensitivities ranged from 33% to 96% and specifi cities from 14% to 100% (fi gure 3).
The meta-analysis from 13 statistically unbiased studies-ie, excluding those with multiple counts from the same sample 24,36 -showed a higher pooled sensitivity of 80% (95% CI 68-88) for the HCS compared with 52% (36-67) for clinical assessment (p=0·008; fi gure 4). Pooled specifi cities were similar at 80% (95% CI 59-91) for the HCS and 75% (56-88) for clinical assessment (p=0·8250).
When we included the eight statistically unbiased studies (without multiple HCS testing) that explicitly compared the HCS with clinical assessment within the same study to diagnose anaemia (median anaemia prevalence: 70% [range , the pooled results were very similar: HCS sensitivity 79% (95% CI 64-88) vs clinical assessment sensitivity 52% (36-67; p=0·0289) and HCS specifi city 77% (52-91) vs clinical assessment specifi city 75% (56-88; p=0·8649). Whether we included all studies or excluded studies that had an unacceptable number of exclusions or withdrawals of participants, did not use an appropriate reference standard, used a noncertifi ed version of the HCS, or a cut-off for anaemia that diff ered from 110 g/L, made little diff erence to the results (table 4) .
For the diagnosis of severe anaemia, the diagnostic accuracy across individual studies showed a similar heterogeneity (specifi cities 19% to 91%; sensitivities 13% to 98%; fi gure 5). In the meta-analysis, the HCS again performed better (p<0·0001), yielding 57% (95% CI 36-76) sensitivity compared with 45% (12-83) by clinical assessment (fi gure 6). Specifi city for the HCS was 99·6% (95% CI 95-99·9)-higher than the estimate of 92% (62-99) for clinical assessment; again we saw little diff erences in the sensitivity analysis (table 4) .
In practice, it is likely that primary health-care workers would use both the HCS and clinical assessment to diagnose anaemia, resulting in a net gain in sensitivity. In studies examining both methods, the sensitivity of a positive result on either the HCS or clinical assessment for anaemia rose to 91% (95% CI 81-96) after excluding studies with inappropriate multiple assessments 24, 36 and an unacceptable amount of missing HCS values. 27 However, to rule out anaemia, results from both methods would have to be negative, which leads to a net loss of specifi city to 59% (95% CI 35-79) for simultaneous testing. 38 For severe anaemia, simultaneous testing would yield a pooled net sensitivity of 83% (95% CI 33-98) in the six comparative studies without multiple assessments for the HCS, whereas the specifi city would decrease to 90% (95% CI 40-99).
Meta-regression analyses did not show a signifi cant eff ect of the covariates population group, anaemia prevalence, reference test, training quantity, and source of blood sample (table 5; appendix p 15), although this could be due to incomplete reporting-eg, for training, or small numbers of studies (with use of appropriate laboratory reference tests).
Discussion
We systematically reviewed the literature to assess the accuracy of the HCS to diagnose anaemia and severe anaemia when used by primary health-care workers in resource-poor settings, and compared this with the accuracy of assessment by clinical signs alone. Publication bias can never be ruled out completely, but the search was comprehensive and no studies were excluded due to language of publication.
We have identifi ed substantial heterogeneity of accuracy outcomes between the selected 14 studies, with sensitivities ranging from 33% to 96% and specifi cities from 14% to 100% for the HCS. We could not fully account for this heterogeneity, possibly because of the small number of studies or incomplete reporting of key *We did the meta-regression analysis for training under the assumption that studies without information on training had less than half day (low) of training. †Point-of-care tests included: HemoCue, fi lter paper cyanmethaemoglobin method, and Sahli's haemometer. ‡Laboratory tests were done in clinical laboratories and included: electronic coulter counter, Hematology Analyzer (HmX), spectrometry method, and laboratory-based cyanmethaemoglobin method. §Blood samples for the HCS and the reference test had either the same origin (capillary, venous, or umbilical cord) or diff erent sources (eg, capillary vs venous). In cases where it was unclear whether the origin was the same, we assumed that the sources of the blood sample were diff erent. methods. Heterogeneity might be explained by diff erences in the quality of methods, anaemia prevalence, training intensity, the choice of the reference test, and the source of the blood sample. Whether the use of diff erent blood samples (capillary, venous, or umbilical cord) between studies could have been a reason for heterogeneity is unclear. Discrepancies between the standard test and the HCS might have been exaggerated by the fact that the origins of the blood samples also varied within at least two studies. 32, 36 Transport conditions or suboptimal storage could potentially have damaged blood specimens in four studies 27, 32, 33, 36 in which the reference test was done in a distant laboratory, although this was not mentioned in the studies.
Table 5: Meta-regression analysis of the eff ect of covariates on HCS accuracy by potential sources of heterogeneity
Intensity of training varied substantially and was poorly reported. We could not identify a relation between training and accuracy outcomes. However, during HCS development, it was shown that trainees' performance improved signifi cantly with further familiarisation, even after receiving an initial 30 min demonstration. 10 Consequently, the original training protocol required two training sessions of about 2 h on 2 consecutive days. Others have shown inter-rater variations even if adhering to the protocol 39 and some have suggested that easy-toread instructions, cartoons, and coloured test strips might improve accuracy. 40 Unfortunately, once the HCS became commercially available, no further evidence was collated to refi ne the training protocol, possibly explaining the variation in training across the included studies.
Although laboratory-based methods remain the gold standard for the measurement of haemoglobin, 5 most studies used the HemoCue, which is easy to use, battery powered, and requires only a small amount of blood because of the use of microcuvettes. Although its accuracy compared against the gold standard is good, venous and arterial samples yield more accurate results than those obtained from capillary blood 5,7,41 and high humidity might alter the functionality of the microcuvettes. 42
Figure 3: Forest plots of all studies diagnosing anaemia by HCS and clinical assessment
HCS=Haemoglobin colour scale. Rusmawatiningtyas (2009) 33 Sinha (2008) 35 van Rheenen (2007) 37 Lindblade (2006p) 29 Gies (2003) 28 Aldridge (2012) 24 Prathapan (2011) 32 Lindblade (2006c) 29 Chathurani (2012) 27 Montresor (2000) 30 van den Broek (1999) 36 Barduagni (2003) 26 Bala (2012) 25 Shah (2014) 34 Montresor (2003) 31 Sinha (2008) 35 Montresor (2000) 30 Chathurani (2012) 27 van den Broek (1999) 36 Gies (2003) 28 Montresor (2003) 31 Lindblade (2006c) 29 Aldridge (2012) 24 Lindblade (2006p) 29 Bala (2012) 25 Clinical signs for diagnosing anaemia Sinha (2008) 35 Bala (2012) 25 Study estimate Summary point 95% confidence region 95% prediction region Montresor (2003) 31 Gies (2003) 28 Aldridge (2012) 24 Lindblade (2006c) 29 Lindblade (2006p) 29 van den Broek (1999) 37 Montresor (2000) 30 Chathurani (2012) 27 Lindblade (2006c) 29 Chathurani (2012) 27 Barduagni (2003) 26 Sinha (2008) 35 Aldridge (2012) 24 Montresor (2000) 30 Shah (2014) 34 van den Broek (1999) 36 Bala (2012) 25 Montresor (2003) 31 Sinha (2008) 35 Aldridge (2012) 24 Bala (2012) 25 Montresor (2000) 30 van den Broek (1999) 36 Montresor (2003) It was also unavoidable that our selection criteria allowed four studies to be included that did not completely comply with the real-life approach with respect to the person who did the HCS assessment. Four studies used cut-off s for the defi nition of anaemia that were not in line with WHO recommendations 19 and we identifi ed fi ve studies that had introduced a high risk of bias, which we handled by excluding them in a sensitivity analysis (table 4) . Two studies introduced statistical bias including multiple counts from the same sample in their analysis, which obliged us to exclude them from the summary estimates, but in most studies (n=12) the possibility of bias was hard to assess due to incomplete reporting of methods.
Despite these limitations, our pooled estimates suggest that in real-life circumstances the HCS signifi cantly improves the accuracy of the diagnosis of anaemia. By clinical examination alone, 48% of patients with mild-tomoderate anaemia would be missed. The HCS alone might signifi cantly reduce this proportion to 20%. Although in study settings both methods were assessed independently, in reality they would be combined as simultaneous tests in addition to the patient's history. We would expect a net gain in sensitivity from 80% (HCS) and 52% (clinical assessment) for the single methods to 91% if the diagnosis of anaemia was considered with either or both methods being positive (severe anaemia: net sensitivity 83%). However, the potential cost of use of both methods simultaneously would be a loss of specifi city.
The public health relevance is best shown by an example: 80% of Malawi's 15 million people live in rural areas; among these are 6·5 million women, of whom 2·7 million have anaemia (anaemia prevalence 45%). Nearly every second woman-ie, 1·3 million-would have the correct diagnosis missed through assessment of the clinical signs only. The HCS alone would reduce the number of underdiagnosed women from 1·3 million to 0·5 million, hence 800 000 additional women would receive the appropriate diagnosis and potentially correct care. If use of both clinical assessment and HCS was combined, more than 1 million additional women would be diagnosed correctly.
Unfortunately, the reduction of underdiagnosis diminishes when anaemia becomes severe. In this case, the HCS leaves 43% undetected, whereas the assessment of clinical signs leaves 55% undetected. The HCS is able to signifi cantly reduce the number of those falsely diagnosed with severe anaemia (0·4% vs 7·6%), hence preventing a large number of patients from unnecessary and potentially harmful blood transfusions or cost-intensive referrals.
Both methods do not signifi cantly diff er between the amount of non-anaemic patients being wrongly diagnosed with mild-to-moderate anaemia, which would be the case by clinical assessment in 25% and with the HCS in 20%. Overdiagnosis of mild-to-moderate anaemia is predominantly an economic issue. It increases expenses for unneeded supplementation therapy or unnecessary further diagnostic investigations in settings where resources are already poor.
However, one advantage of the HCS is that it delivers quantitative results, whereas the clinical assessment is purely qualitative. Although the available studies do not allow an inference about the eff ect of the knowledge of HCS severe anaemia Clinical signs of severe anaemia Shah (2014) 34 Sinha (2008) 35 Montresor (2000) 30 Lindblade (2006p) 29 Lindblade (2006c) 30 Montresor (2003) 31 Bala (2012) 25 Sinha (2008) 35 Aldridge (2012) 24 van den Broek (1999) 36 Montresor (2000) 30 Montresor (2003) 31 Lindblade (2006p) 29 Lindblade (2006c) 29 Bala (2012) 25 continuous values on clinical decisions, such decisions will probably be more strongly aff ected by borderline results close to the defi ned thresholds of severe anaemia than by the clinical assessment alone. Unfortunately, none of the studies assessed the eff ectiveness of the HCS, such as the eff ect on clinical outcomes or its cost-eff ectiveness.
Almost 15 years after it became commercially available, the HCS remains the most simple to use and aff ordable point-of-care device to assess the concentration of haemoglobin quantitatively. However, clinical outcomes depend on the management decisions made by primary health-care workers who have diagnosed anaemia, regardless of the method used. The results from the HCS are prone to individually erroneous readings by individual health-care workers, who in case of discordant results have to decide whether to rely on their clinical judgment or the HCS. Taking into account the potential clinical and economic consequences of misdiagnosis and in view of the evidence that the HCS yields a signifi cantly better sensitivity and a similar specifi city for mild-to-moderate anaemia, but a similarly poor sensitivity and a better specifi city for severe anaemia, we recommend that the HCS result should overrule the clinical judgment in most cases, but for severe anaemia a positive HCS might be over-ruled if clinical signs are missing. Whether a short-term follow-up of patients with discordant or borderline results would improve their clinical outcome remains to be assessed.
Public health decision makers should be aware that the use of the HCS might require more training and supervision than technically more sophisticated devices. To tap the full potential of the HCS, an evidence-based standardised training protocol that has to be as short and cost-eff ective as possible under the pressure of poor resources is urgently needed. Future research should also address endpoints beyond the diagnostic accuracy of the HCS, such as its potential to reduce morbidity and mortality associated with anaemia and the costeff ectiveness of use of the HCS in routine practice.
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